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only the reconstitution of CD4 T cells but not of NK and CD8 T
cells, which might play a role in the CMV-mediated anti-
leukemic effect [6]. Thus, Scheper and colleagues [7] re-Manjappa and colleagues conﬁrmed in the present study
reports by us and others that a cytomegalovirus (CMV)
reactivation is associated with a signiﬁcant relapse risk
reduction in patients with acute myeloid leukemia (AML)
after allogeneic stem cell transplantation (SCT) with mye-
loablative conditioning (MA) [1-3]. This ﬁnding challenged
fundamentally our established perceptions toward CMV
reactivation after SCT. This knowledge evokes, besides
amazement, the insight that we know little about the so-
phisticated immunological processes interacting between
leukemia and a donor-derived immune system that is
challenged by a CMV infection. However, it is of great in-
terest to understand the mechanism by which CMV reac-
tivation increases such an observed antileukemic effect in
AML.
Green and colleagues [2] showed in a large cohort study
that a decreased relapse risk after CMV reactivation was
detectable only in AML at day 100 after transplant, but not in
other diseases such as chronic myeloid leukemia, acute
lymphoblastic leukemia, or lymphoma. These results differed
from those published by Ito and colleagues [4], who observed
that CMV reactivationwas associatedwith a decreased relapse
in a cohort of 110 patients with chronic myeloid leukemia.
Green and colleagues argued that the great majority of pa-
tients in the Ito study received ex vivo T- celledepleted grafts,
which typically results in a robust natural killer (NK) cell
reconstitution after transplant.
In contrast to these results, Thomson et al. [5] found no
association between CMV reactivation and relapse risk in 100
patients with AML who received alemtuzumab, which de-
pletes a variety of immune cells, including NK cells, and
persists in vivo for prolonged periods. Their results are in line
with our results of a retrospective study showing that pa-
tients with AML (n ¼ 64) after myeloablative T celledepleted
transplantation using alemtuzumab did not beneﬁt from a
CMV reactivation. Although alemtuzumab completely abol-
ished the CMV induced antileukemic effect in our study,
antithymocyte globulin (ATG) may have only a moderate
inﬂuence on it according to our observations in a different
cohort of 100 AML patients transplanted from HLA-
mismatched unrelated and sibling donors after using
a myeloablative conditioning regimen (unpublishededgments on page 2.
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13.11.004ported that gamma/delta T cells elicited by CMV reactivation
after allo-SCT cross-recognize CMV and leukemia. They
supposed that this T cell population contributed to the CMV-
induced antileukemic effect. Foley et al. [8] demonstrated
increased populations of interferon-g producing NKG2C1
and NKG2A2 NK cells in SCT recipients as soon as 2 weeks
after CMV viremia was detected. In addition to T cells, NK
cells possess remarkable antileukemic affects against AML in
the transplant setting [9].
But what is the role of a conditioning regimen in this
context? Manjappa and colleagues [1] reported that the
antileukemic effect of a CMV reactivation was only found in
patients receiving MA conditioning (n ¼ 206) but not in pa-
tients who received reduced-intensity conditioning (RIC;
n ¼ 58). What is different about RIC compared with MA
conditioning for the CMV-induced antileukemic effect? In
their smaller RIC cohort, 44 of 58 patients received ATG as part
of their conditioning regimen and a higher proportion of pa-
tients were in ﬁrst complete remission (60%) than in the MA
cohort (44%). Manjappa and colleagues argued that in vivo
T cell depletion by ATG in the RIC cohort may result in miti-
gating the enhanced graft-versus-leukemic effect induced by
CMV reactivation, which underlines the importance of graft-
derived T cells in mediating this effect. Furthermore, they
argued that host-derived memory T cells can persist for up to
6 months in RIC patients and contribute toward immunity
against CMV [1].
Persisting host T cells could contribute to clearing of CMV
upon its reactivation, thereby possibly preventing optimal
donor T cell and NK cell activation that cross-reacts toward
AML. It is unclear, however, whether these differences
explain the distinct mechanism or simply reﬂect other vari-
ables, including a small sample size with insufﬁcient statis-
tical power. On the other hand, it is true that most patients in
the study by Green et al. [2] and in our study [3] received MA
conditioning, which supports this thesis of Manjappa and
colleagues.
Besides the great interest to learn the mechanism of the
protective effect of CMV reactivation, it is ﬁnally of impor-
tance if and how we can clinically use this ﬁnding. Because
it is not justiﬁed to change our CMV treatment strategy due
to the higher therapy-associated mortality of a CMV reac-
tivation after SCT, CMV vaccination might be an option to
induce similar effects without increasing the rate of
therapy-associated mortality. First results from a phase II
study of a CMV vaccine showed a stimulation of speciﬁc
immune responses to CMV [10]. Therefore, it remains to be
seen if CMV vaccination might not only prevent CMV in-
fections but also reduce the relapse risk of patients with
AML. This might be possible if the CMV vaccine induced
O. Fasan / Biol Blood Marrow Transplant 20 (2014) 1e32stimulation of speciﬁc immune responses to CMV in pa-
tients with AML after SCT is potent enough. However, this
effect cannot be expected from new antiviral drugs towards
CMV discussed elsewhere.
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outcomes of mobilizing with high dose etoposide plus GCSF
as compared to cyclophosphamide plus GCSF and platinum
based salvage regimens plus GCSF. Etoposide plus GCSF isPeripheral blood progenitor cell (PBPC) mobilization is
the ﬁrst step in the autologous stem cell transplant (ASCT)
procedure. The regimen used for PBPC mobilization affects
not just the cost of ASCT but also the patient’s total transplant
experience. We often focus on the absolute numeric pro-
genitor cell yield as measured by the CD34þ cell dose in the
mobilized graft; however, the optimal mobilization strategy
should be judged on more than this metric alone. The PBSC
graft quantity and quality affects engraftment kinetics and,
although controversial, may inﬂuence relapse-free survival,
overall survival, and the development of post-transplant
complications such as therapy-related myelodysplastic syn-
drome and acute myeloid leukemia (tMDS/AML) [1-3]. The
choice of whether to mobilize patients using either gran-
ulocyte colony-stimulating factor (G-CSF) alone, G-CSF plus
plerixafor, or chemotherapy plus G-CSF is usually based on
the patient’s disease status, prior therapy, predicted poor
mobilizer status, transplant center protocol, cost consider-
ations, and the individual patient situation. Chemotherapy
plus G-CSF is generally viewed as an attractive strategy to
achieve needed anti-tumor effect and to ensure at least an
adequate (2  106/kg CD34þ cells) or a successful (5  106/
kg CD34þ cells) apheresis yield at a reasonable cost.not a new mobilization regimen, however its utilization
declined following concerns regarding the reported higher
incidence of tMDS/AML following etoposide based mobili-
zation and ASCT [3]. This is probably not so and there are
reports indicating that the incidence of t(MDS/AML) after
etoposide is not signiﬁcantly increased [5e7]. The dose of
etoposide utilized in this retrospective study by Shin Young
Hyun et al. was 1.5g/m2. This dose is lower than the more
conventional 2g/m2. It however appears to have led to an
overall greater number of successful ( 5  106/kg CD34þ
cells) mobilizations at 86% compared to cyclophosphamide
4g/m2 plus GCSF and the platinum based regimens (ICE,
DHAP and ESHAP) plus GCSF at 45% and 61% respectively
(p¼0.004). The success of this lower dose is in keeping with
the observation by Kanfer et al., that reducing the dose of
etoposide to 1.6g/m2 or 1.8g/m2 resulted in adequate and
successful mobilizations compared to higher doses. An even
lower dose of etoposide (0.75g/m2) was utilized with suc-
cess in patients with multiple myeloma, some of whom
were predicted poor mobilizers [8]. Consistent across all
reports of high and intermediate dose etoposide based
mobilization is the high incidence of neutropenic fever
compared to growth factor based strategies where the
incidence is zero. The incidence of 67% in this report is
higher than previously reported rates that range from of
17e 27%. This complication unfortunately increases the cost
and inconvenience to patients due to the need for read-
mission for intravenous antibiotics. There is more myelo-
suppression and utilization of blood products with all
chemo-mobilization based strategies; however in this
report etoposide plus GCSF induced a signiﬁcantly lower
